Retatrutide, explained calmly

What this guide covers

The 'triple G' drug everyone is asking about: what retatrutide is, what the Phase 2 trial actually showed, where the Phase 3 program stands, and why there is no safe or legal way to take it yet. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer. Retatrutide is Eli Lilly's investigational once-weekly injection that activates three receptors at once: GLP-1, GIP, and glucagon. Semaglutide (Ozempic, Wegovy) hits one of those, tirzepatide (Mounjaro, Zepbound) hits two, and retatrutide adds the third, which is why people call it the 'triple G.' In its Phase 2 obesity trial it produced the largest average weight reduction reported for any anti-obesity medication at that stage, roughly 24 percent at 48 weeks on the highest dose. It is not FDA approved, it is not legally for sale anywhere, and the Phase 3 trials that will decide its future are still the gate it has to pass.
• What a third receptor adds. The GLP-1 and GIP parts work the way readers of this site already know: appetite reduction, slower gastric emptying, better insulin response after meals. The new ingredient is glucagon receptor agonism. Glucagon is usually thought of as the hormone that raises blood sugar, but activating its receptor also increases energy expenditure and drives the liver to burn fat. The bet behind retatrutide is that adding a calorie-burning signal to two appetite-reducing signals beats appetite reduction alone. The Phase 2 liver-fat data was striking: among participants with fatty liver disease, most saw liver fat drop to normal ranges. The trade-off is that glucagon agonism also nudges heart rate up, which is one of the things Phase 3 is watching closely.
• What the Phase 2 trial actually showed. The trial that created the headlines was published in the New England Journal of Medicine in 2023: 338 adults with obesity, randomized to placebo or one of four retatrutide doses for 48 weeks. The highest dose averaged about 24 percent body-weight reduction, and the trial had not plateaued when it ended, meaning the final number with longer treatment could be higher. For calibration against the approved drugs: semaglutide's flagship trial averaged about 15 percent at 68 weeks and tirzepatide's about 21 percent at 72 weeks. Those are different trials with different durations and populations, not a head-to-head, and Phase 2 results regularly shrink in Phase 3. Impressive is the honest word; proven is not yet available.
• Where Phase 3 stands. Lilly's Phase 3 program, called TRIUMPH, is running multiple large trials in obesity and related conditions, including obstructive sleep apnea and knee osteoarthritis, alongside diabetes studies. These trials enroll thousands of participants and run well over a year each. As of mid-2026 retatrutide remains investigational: no FDA submission has been approved, and any timeline you read is an estimate that moves with the data. When the TRIUMPH results publish, this page gets updated with a dated note, that is our standing practice. Until then, every concrete claim about retatrutide rests on 338 people followed for 48 weeks.
• The side-effect picture so far. Phase 2 looked familiar to anyone who knows this drug class: nausea, diarrhea, vomiting and constipation led the list, dose-dependent and concentrated during dose escalation. Two signals stand out as retatrutide-specific watch items. Heart rate rose measurably, peaking mid-trial and partly settling by week 48, a known glucagon-receptor effect. And a subset of participants reported unusual skin sensitivity. Neither derailed the program; both are exactly what Phase 3 safety monitoring exists to settle. We keep a fuller, sourced breakdown in our retatrutide side-effects guide.

Frequently asked questions